Nontuberculous mycobacteria (NTM) represent more than 200 species and subspecies, some of which can produce chronic infection in the lungs and other organs. Among the NTM, Mycobacterium avium complex (MAC) is the most prominent. Guidelines issued in 2020 are helpful to guide the management of patients with NTM lung disease (NTM-LD). Nonetheless, care is highly individualized through collaboration by an interprofessional team of experienced clinicians. In this case-based activity, our expert faculty provide their insight to address challenges encountered in everyday clinical practice. Their discussion highlights real-world best practices in diagnosis and treatment initiation and modification based on guideline recommendations for MAC-LD, recent scientific and therapeutic advances, strategies for optimizing treatment adherence and completion, and the importance of shared decision-making with interprofessional collaborative care.
Course Credit:
1.50 ACPE Contact Hours
1.50 AMA PRA Category 1 CreditsTM
1.50 ANCC Contact Hours
Dates:
Opens: 2022-08-31
Closes: 2023-08-31
Target Audience:
This activity was developed for pulmonologists, infectious disease specialists, nurse practitioners, nurses, pharmacists, and other clinicians who have a role in the diagnosis and treatment of patients with nontuberculous mycobacterial lung disease.
This activity is supported by an Educational Grant from Insmed.
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.50 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.50 contact hours.
Additional Content Planners
Melissa Badowski, PharmD, MPH, BCIDP, BCPS, AAHIVP (Medical Writer)No significant relationships to disclose.
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Jennifer Faber-Gerling, RN, MS, CNS, NP-BC
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado -
David E. Griffith, MD
Professor of Medicine
National Jewish Health
Denver, Colorado -
Christina O'Connor, PharmD, BCPS, AAHIV-P
Antimicrobial Stewardship Clinical Pharmacist Manager
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine and Science
Rochester, Minnesota
Presenting Faculty
Downloads
Learning Objectives
- Describe best practices to ensure a timely diagnosis and initiation of guideline-based treatment for nontuberculous mycobacterial lung disease (NTM-LD)
- Explain the clinical impact of recent scientific and therapeutic advances in NTM-LD
- Create individualized treatment plans for patients with NTM-LD that align with the latest guidelines and clinical advances
- Apply strategies for optimal collaboration with patients with NTM-LD, including shared decision making
Faculty Disclosures
Jennifer Faber-Gerling, RN, MS, CNS, NP-BC
Speakers Bureau: Insmed, Inc
David E. Griffith, MD
Consultant: AN2 Therapeutics, Insmed Inc, MannKind Corp, Paratek Pharmaceuticals
Research Support: Insmed, Inc
Speakers Bureau: Insmed, Inc
Christina O'Connor, PharmD, BCPS, AAHIV-P
Research Support: Gilead
Speakers Bureau: CEimpact, Gilead, Insmed, Inc, Jobson Healthcare